The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone. (January 2019)
- Record Type:
- Journal Article
- Title:
- The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone. (January 2019)
- Main Title:
- The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone
- Authors:
- Brunetti, Luigi
Lee, Seung-Mi
Nahass, Ronald G.
Suh, David
Miao, Benjamin
Bucek, John
Kim, Dongwon
Kim, Ok-Kyu
Suh, Dong-Churl - Abstract:
- Highlights: Concomitant use of amiodarone and levofloxacin increased cardiac risks by five times. Drug-related death was not increased in concomitant levofloxacin and amiodarone. The use of amiodarone with levofloxacin should be avoided whenever possible. Abstract: Objectives: Levofloxacin and amiodarone are both known to prolong the QT interval. This study was conducted to estimate the risk of cardiac events in patients receiving concomitant levofloxacin and amiodarone. Methods: The study included patients who were admitted to a large academic community medical center from 1/2012 to 12/2015 and received both levofloxacin and amiodarone at some point during their hospitalization. Patients received concomitant or non-concomitant levofloxacin and amiodarone during hospitalization. The primary outcome was the occurrence of cardiac events during therapy. The secondary outcome was the proportion of patients with an electrocardiogram performed before and after initiation of therapy. Odds ratios for cardiac events were calculated using a multivariable logistic regression model with and without adjusting for the study variables. The concomitant group was further evaluated for predictors of the primary outcome using multivariable logistic regression. Results: This study included 240 patients, 164 (68.3%) of whom received concomitant levofloxacin and amiodarone. Concomitant medication therapy was associated with a greater than six-fold increased risk of cardiac events after adjustingHighlights: Concomitant use of amiodarone and levofloxacin increased cardiac risks by five times. Drug-related death was not increased in concomitant levofloxacin and amiodarone. The use of amiodarone with levofloxacin should be avoided whenever possible. Abstract: Objectives: Levofloxacin and amiodarone are both known to prolong the QT interval. This study was conducted to estimate the risk of cardiac events in patients receiving concomitant levofloxacin and amiodarone. Methods: The study included patients who were admitted to a large academic community medical center from 1/2012 to 12/2015 and received both levofloxacin and amiodarone at some point during their hospitalization. Patients received concomitant or non-concomitant levofloxacin and amiodarone during hospitalization. The primary outcome was the occurrence of cardiac events during therapy. The secondary outcome was the proportion of patients with an electrocardiogram performed before and after initiation of therapy. Odds ratios for cardiac events were calculated using a multivariable logistic regression model with and without adjusting for the study variables. The concomitant group was further evaluated for predictors of the primary outcome using multivariable logistic regression. Results: This study included 240 patients, 164 (68.3%) of whom received concomitant levofloxacin and amiodarone. Concomitant medication therapy was associated with a greater than six-fold increased risk of cardiac events after adjusting for the study variables (Odds Ratio = 6.20; 95% Confidence Interval = 1.34–28.62). Conclusions: Patients receiving concomitant amiodarone and levofloxacin experienced a five-fold increase in cardiac events compared to patients given either medication alone. … (more)
- Is Part Of:
- International journal of infectious diseases. Volume 78(2019)
- Journal:
- International journal of infectious diseases
- Issue:
- Volume 78(2019)
- Issue Display:
- Volume 78, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 78
- Issue:
- 2019
- Issue Sort Value:
- 2019-0078-2019-0000
- Page Start:
- 50
- Page End:
- 56
- Publication Date:
- 2019-01
- Subjects:
- Levofloxacin -- Amiodarone -- Cardiac risk -- Cardiac death -- QT interval
Communicable diseases -- Periodicals
Communicable Diseases -- Periodicals
Communicable diseases
Periodicals
Electronic journals
616.9 - Journal URLs:
- http://bibpurl.oclc.org/web/73769 ↗
http://www.journals.elsevier.com/international-journal-of-infectious-diseases/ ↗
http://www.sciencedirect.com/science/journal/12019712 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/12019712 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/12019712 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.ijid.2018.10.017 ↗
- Languages:
- English
- ISSNs:
- 1201-9712
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.304750
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9139.xml